Comparative Pharmacology
Head-to-head clinical analysis: DANTRIUM versus PARSIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTRIUM versus PARSIDOL.
DANTRIUM vs PARSIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (RyR1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.
Parsidol (ethopropazine) is a phenothiazine derivative that acts as an anticholinergic agent. It inhibits the action of acetylcholine at muscarinic receptors, thereby reducing cholinergic activity in the basal ganglia and restoring the balance between dopaminergic and cholinergic neurotransmission. It also has some dopamine reuptake inhibition and antihistaminic properties.
Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.
Oral: 2.5-5 mg twice daily, gradually increased to 5-10 mg three times daily; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8.7-14.4 hours in adults; longer with hepatic dysfunction.
Terminal elimination half-life: 12-24 hours (prolonged in elderly and renal impairment, requiring dose adjustment).
Renal: ~65% as unchanged drug; biliary/fecal: ~15% as metabolites; remainder metabolized and eliminated via urine.
Renal: 60-70% as unchanged drug; biliary/fecal: 15-20% as metabolites; minor respiratory elimination.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant